Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eden Tedla

Physician Assistant Charlotte, NC Physician Assistant

NPI 1013437342 CMS profile 11162076

200 Hawthorne Ln, Charlotte, NC 28204

Open in the dashboard

General payments

$8,888

380 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eden Tedla of Charlotte, NC is reported in the CMS Open Payments database as having received $8,888 across 380 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $733 31
2024 General $1,475 59
2023 General $2,063 95
2022 General $2,302 90
2021 General $2,315 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eden Tedla
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Eden Tedla were reported at $733. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Eden Tedla Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,315 $132 $37–$438 $132
2022 $2,302 $155 $48–$522 $149
2023 $2,063 $167 $52–$557 $160
2024 $1,475 $178 $55–$600 $164
2025 $733 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $1,355 49 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,083 36 payments
  3. AbbVie, Inc. $981 44 payments
  4. AstraZeneca Pharmaceuticals LP $911 31 payments
  5. Novartis Pharmaceuticals Corporation $719 30 payments
  6. Gilead Sciences, Inc. $659 26 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $550 27 payments
  8. Pfizer Inc. $448 29 payments
  9. Paratek Pharmaceuticals, Inc. $346 22 payments
  10. Alnylam Pharmaceuticals Inc. $291 13 payments
  11. Other $1,543 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,888 380 payments
Products named General payments · program years 2021–2025
  1. XARELTO $1,355 49 payments
  2. TEFLARO $727 29 payments
  3. JARDIANCE Diabetes $614 22 payments
  4. DALVANCE $581 27 payments
  5. XIFAXAN $550 27 payments
  6. JARDIANCE Diabetes $463 14 payments
  7. ELIQUIS $433 28 payments
  8. ENTRESTO $398 18 payments
  9. NUZYRA $346 22 payments
  10. GIVLAARI $291 13 payments
  11. Other $4,429 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$1,488

Medicare's payments for the services billed

Medicare patients

17

Average age 69

Services billed

21

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $284
$284 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $145
$145 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $144
$144 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
DALVANCE
  • AbbVie, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record